S&P 500 Futures
(0.22%) 5 142.75 points
Dow Jones Futures
(0.21%) 38 521 points
Nasdaq Futures
(0.31%) 17 900 points
Oil
(-0.99%) $83.02
Gas
(1.56%) $1.953
Gold
(-0.32%) $2 339.70
Silver
(-0.27%) $27.46
Platinum
(0.29%) $924.80
USD/EUR
(-0.17%) $0.933
USD/NOK
(-0.13%) $11.01
USD/GBP
(-0.24%) $0.798
USD/RUB
(0.78%) $92.59

リアルタイムの更新: Nippon Shinyaku Co., Ltd. [NPPNY]

取引所: OTC セクター: Healthcare 産業: Drug Manufacturers—Specialty & Generic
最終更新日時25 4月 2024 @ 23:59

0.00% $ 6.93

Live Chart Being Loaded With Signals

Commentary (25 4月 2024 @ 23:59):

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments...

Stats
本日の出来高 154.00
平均出来高 91.00
時価総額 1.87B
EPS $27.56 ( 2023-09-30 )
Last Dividend $0.105 ( 2022-09-29 )
Next Dividend $0 ( N/A )
P/E 11.94
ATR14 $0 (0.00%)

Nippon Shinyaku Co., Ltd. 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Nippon Shinyaku Co., Ltd. 財務諸表

Annual 2023
収益: $144.18B
総利益: $88.20B (61.17 %)
EPS: $338.70
FY 2023
収益: $144.18B
総利益: $88.20B (61.17 %)
EPS: $338.70
FY 2022
収益: $137.48B
総利益: $87.29B (63.49 %)
EPS: $370.97
FY 2021
収益: $121.89B
総利益: $71.93B (59.02 %)
EPS: $76.84

Financial Reports:

No articles found.

Nippon Shinyaku Co., Ltd. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.105
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Nippon Shinyaku Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.36 - Stable (27.22%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.0575 2017-10-02
Last Dividend $0.105 2022-09-29
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 11 --
Total Paid Out $1.029 --
Avg. Dividend % Per Year 0.00% --
Score 4.11 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 6.36
Div. Directional Score 10.00 --
Next Divdend (Est)
(2024-05-07)
$0 Estimate 0.00 %
Dividend Stability
0.09 Very Bad
Dividend Score
4.11
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TRBK Ex Dividend Junior 2023-08-03 Semi-Annually 0 0.00%
ITJTY Ex Dividend Junior 2023-10-31 Annually 0 0.00%
BKKPF Ex Dividend Junior 2023-09-06 Annually 0 0.00%
PUODY Ex Dividend Knight 2023-06-21 Annually 0 0.00%
EPOKY Ex Dividend Knight 2023-10-23 Semi-Annually 0 0.00%
VDMCY Ex Dividend Knight 2023-06-22 Semi-Annually 0 0.00%
KSBI Ex Dividend Knight 2023-07-28 Quarterly 0 0.00%
CGEMY Ex Dividend Knight 2023-05-25 Annually 0 0.00%
SCGLY Ex Dividend Junior 2023-05-25 Annually 0 0.00%
FSUGY Ex Dividend Knight 2023-09-07 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1641.5006.7210.00[0 - 0.5]
returnOnAssetsTTM0.09741.2006.758.10[0 - 0.3]
returnOnEquityTTM0.1171.5009.8110.00[0.1 - 1]
payoutRatioTTM0.331-1.0006.69-6.69[0 - 1]
currentRatioTTM5.920.80010.008.00[1 - 3]
quickRatioTTM4.170.80010.008.00[0.8 - 2.5]
cashRatioTTM2.111.50010.0010.00[0.2 - 2]
debtRatioTTM0.00826-1.5009.86-10.00[0 - 0.6]
interestCoverageTTM264.201.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM321.862.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM163.502.0010.0010.00[0 - 20]
debtEquityRatioTTM0.00953-1.5009.96-10.00[0 - 2.5]
grossProfitMarginTTM0.6461.0002.572.57[0.2 - 0.8]
operatingProfitMarginTTM0.2261.0007.477.47[0.1 - 0.6]
cashFlowToDebtRatioTTM10.591.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.5930.8009.387.50[0.5 - 2]
Total Score13.73

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM3.061.0009.790[1 - 100]
returnOnEquityTTM0.1172.509.8810.00[0.1 - 1.5]
freeCashFlowPerShareTTM163.502.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.009611.5009.760[0 - 0.4]
operatingCashFlowPerShareTTM321.862.0010.0010.00[0 - 30]
payoutRatioTTM0.3311.5006.69-6.69[0 - 1]
pegRatioTTM0.0006931.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1471.0008.810[0.1 - 0.5]
Total Score6.36

Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。